Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study
- 148 Downloads
A “biosimilar” is a biotechnological product with a lower cost profile and equivalent efficacy and safety to the originator, but post-marketing clinical evaluation of biosimilar products has not been adequately conducted. We prospectively investigated the utility of biosimilar filgrastim in 13 peripheral blood stem cell (PBSC) donors from June 2014 to January 2017. In addition, we retrospectively compared these to another 13 PBSC donors mobilized with the originator filgrastim in the same period. Donor characteristics were equivalent between the groups. The median number of CD34+ cells per donor body weight (BW) and blood volume processed (BV) were 4.87 × 106/kg and 25.5 × 103/mL in the biosimilar group and 4.93 × 106/kg and 16.6 × 103/mL in the originator group, respectively. There were no significant differences between the groups in the number of CD34+ cells per donor BW or BV. All adverse events associated with G-CSF were permissive. The total G-CSF cost was significantly lower in the biosimilar group than in the originator group. These findings suggest that biosimilar filgrastim has the same efficacy and short-term safety as originator filgrastim for PBSC mobilization in healthy donors, with economic superiority. Longer follow-up studies are needed to evaluate the incidence of long-term adverse events.
KeywordsBiosimilar Granulocyte colony-stimulating factor Hematopoietic stem cell mobilization
We thank the inpatient nursing team and the support staff for the excellent care they provided to our donors, patients and their families.
Funding was provided by Kyowa Hakko Kirin and Fuji Pharma.
Compliance with ethical standards
Conflict of interest
SN received research grants from Fuji Pharma Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. Other authors declare no conflict of interest.
- 1.Duong HK, Savani BN, Copelan E, Devine S, Wingard JR, Shaughnessy P, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262–73. https://doi.org/10.1016/j.bbmt.2014.05.003.CrossRefPubMedGoogle Scholar
- 2.Harada K, Yamada Y, Konishi T, Nagata A, Takezaki T, Kaito S, et al. Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2016;104(6):709–19. https://doi.org/10.1007/s12185-016-2085-0.CrossRefPubMedGoogle Scholar
- 8.Farhan R, Urbanowska E, Zborowska H, Król M, Torosian T, Piotrowska I, et al. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors. Ann Hematol. 2017;96(10):1735–9. https://doi.org/10.1007/s00277-017-3060-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011;96(7):942–7. https://doi.org/10.3324/haematol.2011.045740.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Chen SH, Yang SH, Chu SC, Su YC, Chang CY, Chiu YW, et al. The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization. Int J Hematol. 2011;93:652–9. https://doi.org/10.1007/s12185-011-0844-5.CrossRefPubMedGoogle Scholar